{"id":"W2975141952","doi":"10.1056/nejmoa1910962","title":"Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","year":2019,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2262,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre; McGill University","funders":"Eisai; Pacira BioSciences; Mylan; Clovis Oncology; Pacira Pharmaceuticals; Karyopharm Therapeutics; F. Hoffmann-La Roche; Roche; GlaxoSmithKline; Takeda Oncology; Amgen; Pfizer; Fujirebio US; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Ovarian cancer; Medicine; Oncology; Cancer; Gynecology; Internal medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01026469645237137,"score_gpt":0.2782807913748217,"score_spread":0.2680160949224503,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}